Show simple item record

dc.contributor.authorHampel, Harald
dc.contributor.authorO'Bryant, Sid E
dc.contributor.authorMolinuevo, José L
dc.contributor.authorZetterberg, Henrik
dc.contributor.authorMasters, Colin L
dc.contributor.authorLista, Simone
dc.contributor.authorKiddle, Steven
dc.contributor.authorBatrla, Richard
dc.contributor.authorBlennow, Kaj
dc.date.accessioned2018-11-23T00:32:00Z
dc.date.available2018-11-23T00:32:00Z
dc.date.issued2018-11
dc.identifier.issn1759-4758
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/285802
dc.description.abstractBiomarker discovery and development for clinical research, diagnostics and therapy monitoring in clinical trials have advanced rapidly in key areas of medicine - most notably, oncology and cardiovascular diseases - allowing rapid early detection and supporting the evolution of biomarker-guided, precision-medicine-based targeted therapies. In Alzheimer disease (AD), breakthroughs in biomarker identification and validation include cerebrospinal fluid and PET markers of amyloid-β and tau proteins, which are highly accurate in detecting the presence of AD-associated pathophysiological and neuropathological changes. However, the high cost, insufficient accessibility and/or invasiveness of these assays limit their use as viable first-line tools for detecting patterns of pathophysiology. Therefore, a multistage, tiered approach is needed, prioritizing development of an initial screen to exclude from these tests the high numbers of people with cognitive deficits who do not demonstrate evidence of underlying AD pathophysiology. This Review summarizes the efforts of an international working group that aimed to survey the current landscape of blood-based AD biomarkers and outlines operational steps for an effective academic-industry co-development pathway from identification and assay development to validation for clinical use.
dc.description.sponsorshipI recieved an honorarium from Roche Diagnostics for my participation in the advisory panel meeting leading to this paper
dc.format.mediumPrint
dc.languageeng
dc.publisherSpringer Science and Business Media LLC
dc.subjectHumans
dc.subjectAlzheimer Disease
dc.subjectEarly Diagnosis
dc.subjectBiomarkers
dc.subjectPrecision Medicine
dc.titleBlood-based biomarkers for Alzheimer disease: mapping the road to the clinic.
dc.typeArticle
prism.endingPage652
prism.issueIdentifier11
prism.publicationDate2018
prism.publicationNameNat Rev Neurol
prism.startingPage639
prism.volume14
dc.identifier.doi10.17863/CAM.33146
rioxxterms.versionofrecord10.1038/s41582-018-0079-7
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.licenseref.startdate2018-11
dc.contributor.orcidKiddle, Steven [0000-0003-4350-7437]
dc.identifier.eissn1759-4766
rioxxterms.typeJournal Article/Review
pubs.funder-project-idMedical Research Council (MR/P021573/1)
cam.issuedOnline2018-10-08
rioxxterms.freetoread.startdate2019-11-30


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record